PUBLISHER: IMARC | PRODUCT CODE: 1800855
PUBLISHER: IMARC | PRODUCT CODE: 1800855
The global apheresis equipment market size reached USD 2.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 5.7 Billion by 2033, exhibiting a growth rate (CAGR) of 7.63% during 2025-2033.
Apheresis equipment is used to remove specific constituents from the blood, such as the cells, plasma, platelets or leukocytes, using either centrifugal or membrane filtration methods. The remaining blood components are then reintroduced into the bloodstream of the donor or patient. It finds application in blood banks and the treatment of various medical conditions. In recent years, the introduction of modern apheresis equipment has led to the development of advanced features, such as auto elutriation and fluid flow dynamics, and has enabled the collection of platelets or red blood cells (RBCs) concentrates.
Due to the spread of the coronavirus disease (COVID-19) and lack of an effective vaccine or treatment, convalescent plasma therapy is emerging as a measure for treating critically ill patients. Apheresis equipment is utilized in this therapy to collect convalescent plasma (CP) from fully recovered patients and transfuse it to active patients as a source of antibodies. Besides this, the growing prevalence of chronic diseases and neurological disorders, along with the rising number of blood donors, is also contributing to the market growth. Moreover, favorable reimbursement policies, coupled with improving healthcare infrastructure, are also driving the sales of apheresis equipment around the world. Other factors, such as the introduction of advanced variants with automated interface systems, screen navigation and graphical user interface displays, along with the increasing investments in research and development (R&D) activities, are expected to create a positive outlook for the market in the coming years.
The report has also analysed the competitive landscape of the market with some of the key players being Asahi Kasei Corporation, B. Braun Melsungen Aktiengesellschaft, Baxter International Inc., Fresenius Kabi Aktiengesellschaft (Fresenius SE & Co. KGaA), Haemonetics Corporation, Hemacare Corporation (Charles River Laboratories Inc.), Kaneka Corporation, Kawasumi Laboratories Inc., Medica SpA, Nikkiso Co Ltd. and Terumo BCT Inc. (Terumo Corporation).